All News

gout.bunion.jpg

Ironwood Retreats from the US Gout Market

d Jack Cush, MD

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019.

Read Article
cancer.cross_.jpg

No Rise in Cancer Risk with Actemra

d RheumNow

In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.

Read Article
180px-Cannabis_Plant.jpg

CRA Position Statement on Medical Cannabis Use

d Jack Cush, MD

Courtesy of the Canadian Rheumatology Association (CRA) website, here are consensus guidelines on medical cannabis use.



Rheumatology patients experience prevalent pain that is only modestly controlled with current treatment strategies.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – You Owe Me a DEXA (3.15.19)

d Jack Cush, MD

Dr. Jack Cush reviews this week's news and highlights from RheumNow.com.

Read Article
Muscle (keep)

Brazilian Guidelines for Systemic Autoimmune Myopathies

d Jack Cush, MD

The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).

Read Article
TNF%20blockers.jpg

Lower TNF Inhibitor Persistence in Spondylitis

d Jack Cush, MD

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

Read Article
fever2.jpg

First Line IL-1 Inhibition in Systemic JIA

d RheumNow

First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.

Read Article
Vedolizumab superior to adalimumab in clinical remission (31 vs 22%) and mucosal healing(40 vs 28%) at week 52 when given to383 patients with moderate to severely active ulcerative colitis. Data presented at European Crohn’s and Colitis Congress. https://t.co/dXrEkzhnKh

Links:

Dr. John Cush RheumNow ( View Tweet)

Daily noninvasive ultrasound (US) stimulation of the spleen significantly reduces disease severity in a murine model of inflammatory arthritis. Results mediated via T & B cell effects as T/B deficient mice did not improve with splenic US. https://t.co/dSlYWEgplR

Links:

Dr. John Cush RheumNow ( View Tweet)

The Weekly RheumNow Podcast is up! https://t.co/qA4wADpPN8 or listen to it on iTunes or SoundCloud https://t.co/mZ3y0yvwA3

Links:

Dr. John Cush RheumNow ( View Tweet)

FREE-Register to view into RheumNow Live next friday 3/22 >> https://t.co/lbrJ0Dp1Hb AFabulous Faculty - Calabrese, O'Shea, Weinblatt, Ruderman, Reveille, Langford, Seo, Kavanaugh, Conaghan, VanVollenhoven, Schett, Matteson, Wolfe, Pincus & more https://t.co/0NwHXWfjyO

Links:

Dr. John Cush RheumNow ( View Tweet)

2,933 adults >50 yrs went to the ER with a new vertebral fracture (2008-2014) but 98% did not have a DXA in 2yrs before and 1 yr after; and only 7% started OP Rx; In the ensuing 2 yrs, 38% developed another Fx https://t.co/JYYLFawV5z

Links:

Dr. John Cush RheumNow ( View Tweet)

QD44 - RA and Gout https://t.co/5a4rtwt1dw via @YouTube

Links:

Dr. John Cush RheumNow ( View Tweet)

#1 Humira tops list of top selling drugs of 2018 at $19.9 Billion worldwide sales. Other Rheum drugs include #6 Rituxan $6.9 billion and #10 Stelara $5.2 billion https://t.co/mj5nTIQHL0

Links:

Dr. John Cush RheumNow ( View Tweet)

Study from American Academy of Orthopaedic Surgeons' annual meeting in Las Vegas shows that 1 in 3 US kids (ages 10 -18 yrs) have back pain - from a survey of 3,700 kids. Risk increases w/ age, weight, playing competitive sports. https://t.co/p0KyXQVPYU

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - Secondary Loss of Efficacy | RheumNow - Her 1st TNFi fails after 2 years - then what? https://t.co/owAT4YZuBG

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - Shingles Happens | RheumNow - How to prevent and manage Shingles https://t.co/pdvsvuzcsd

Links:

Dr. John Cush RheumNow ( View Tweet)

GSK has issued a new safety warning on Benlysta with a low frequency risk of serious depression & suicidal ideation; new data added to PI based on new 4003 SLE pt trial with Suicidal ideation seen in 0.7% on BEL and 0.2% on PBO; depression (0.3% vs <0.1%) https://t.co/cMp52MLKxs

Links:

Dr. John Cush RheumNow ( View Tweet)

You can attend RheumNow Live for Free via online access - Innovative lectures and Q&A Panels beginning friday afternoon 3/22, ending Sunday 3/24. Register for FREE at https://t.co/lbrJ0Dp1Hb

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 1021 Scleroderma patients from the EUSTAR cohort shows progressive skin fibrosis (>5 mRSS in 1 yr) was associated with significant lung function decline (FVC worse ≥10% (53.6% vs 34.4%; p<0.001) and all-cause mortality (15.4% vs 7.3%; p=0.003). https://t.co/VNX3rF1LUH

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×